Characteristics of AML patient samples
AML sample . | FAB . | NPM mutation . | FLT3 . | Karyotype . | Total CD34+ % . | Subtype . |
---|---|---|---|---|---|---|
1 | M1 | TCTG | ITD | Normal | 0.14 | A |
2 | M1 | TCTG | WT | Normal | 0.05 | A |
3 | M2 | TCTG | WT | Normal | 0.05 | A |
4 | M4 | TCTG | WT | Normal | 0.15 | A |
5 | M4 | TCTG | ITD | 47,XX,+13 | 0.1 | A |
6 | M4 | TCTG | WT | Normal | 0.12 | A |
7 | M5 | TCTG | WT | 47,XX,+der(?)t(1;?)(q21;?) | 0.19 | A |
8 | M1 | CCTG | WT | Failed | 0.13 | A |
9 | M1 | TCTG | ITD | Normal | 0.28 | A |
10 | M2 | CATG | WT | 46,XX,del(11)(p11.2p13)[7]; 46,idem,t(2;3)(q33;p11∼p13)[3] | 0.06 | A |
11 | M2 | TCTG | ITD | Normal | 0.06 | A |
12 | M5 | TCTG | WT | Normal | 0.25 | A |
13 | M5 | TCTG | WT | Normal | 0.085 | A |
14 | M4 | TCTG | WT | 48,XY,+3 +10 | 5.5 | B |
15 | M5 | TCTG | WT | Normal | 3.1 | B |
16 | M5 | TCTG | ITD | Normal | 0.66 | B |
17 | M1 | CTTG | ITD | Normal | 0.85 | C |
18 | M4 | TCTG | ITD | Normal | 8.0 | C |
19 | M4 | CCTG | ITD | Normal | 11.1 | C |
20 | M1 | TCTG | NT | Normal | 53.2 | C |
21 | M1 | TCTG | WT | 47,XY,+13 | 3.3 | C |
22 | M4 | CCAG | ITD | Normal | 3.7 | C |
23 | M2 | CCTG | ITD | Normal | 1.9 | C |
24 | NT | TCTG | ITD | Normal | 26.9 | C |
25 | M1 | TCTG | ITD | Normal | 65.3 | C |
26 | M2 | CCTG | ITD | Normal | 8.6 | C |
27 | M1 | TCTG | WT | Normal | 2.4 | C |
AML sample . | FAB . | NPM mutation . | FLT3 . | Karyotype . | Total CD34+ % . | Subtype . |
---|---|---|---|---|---|---|
1 | M1 | TCTG | ITD | Normal | 0.14 | A |
2 | M1 | TCTG | WT | Normal | 0.05 | A |
3 | M2 | TCTG | WT | Normal | 0.05 | A |
4 | M4 | TCTG | WT | Normal | 0.15 | A |
5 | M4 | TCTG | ITD | 47,XX,+13 | 0.1 | A |
6 | M4 | TCTG | WT | Normal | 0.12 | A |
7 | M5 | TCTG | WT | 47,XX,+der(?)t(1;?)(q21;?) | 0.19 | A |
8 | M1 | CCTG | WT | Failed | 0.13 | A |
9 | M1 | TCTG | ITD | Normal | 0.28 | A |
10 | M2 | CATG | WT | 46,XX,del(11)(p11.2p13)[7]; 46,idem,t(2;3)(q33;p11∼p13)[3] | 0.06 | A |
11 | M2 | TCTG | ITD | Normal | 0.06 | A |
12 | M5 | TCTG | WT | Normal | 0.25 | A |
13 | M5 | TCTG | WT | Normal | 0.085 | A |
14 | M4 | TCTG | WT | 48,XY,+3 +10 | 5.5 | B |
15 | M5 | TCTG | WT | Normal | 3.1 | B |
16 | M5 | TCTG | ITD | Normal | 0.66 | B |
17 | M1 | CTTG | ITD | Normal | 0.85 | C |
18 | M4 | TCTG | ITD | Normal | 8.0 | C |
19 | M4 | CCTG | ITD | Normal | 11.1 | C |
20 | M1 | TCTG | NT | Normal | 53.2 | C |
21 | M1 | TCTG | WT | 47,XY,+13 | 3.3 | C |
22 | M4 | CCAG | ITD | Normal | 3.7 | C |
23 | M2 | CCTG | ITD | Normal | 1.9 | C |
24 | NT | TCTG | ITD | Normal | 26.9 | C |
25 | M1 | TCTG | ITD | Normal | 65.3 | C |
26 | M2 | CCTG | ITD | Normal | 8.6 | C |
27 | M1 | TCTG | WT | Normal | 2.4 | C |
The subtype refers to the classification based on the pattern of expression of CD34 and CD38. All samples except samples 25 and 26 have wild-type Wilms tumor 1 exons 7 and 9 (sample 18 was not tested).
FAB indicates French-American-British classification; NPM, nucleophosmin; FLT3, FMS-like tyrosine kinase; WT, wild type; ITD, internal tandem duplication; T, thymine; C, cytosine; G, guanine; and A, adenine.